✦ LIBER ✦

High Dose Cytosine Arabinoside in the Management of Refractory Acute Leukaemia

✍ Scribed by Willemze, R. ;Zwaan, F. E. ;Colpin, G. ;Keuning, J. J.

Book ID: 114789786
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Weight: 311 KB
Volume: 29
Category: Article
ISSN: 0036-553X
DOI: 10.1111/j.1600-0609.1982.tb00575.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA WITH HIGH DOSE CYTOSINE ARABINOSIDE

✍ R. Willemze; F. E. Zwaan; J. J. Keuning; G. Colpin 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

High dose cytosine arabinoside (HDARAC)

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Clofarabine and high-dose cytosine arabi

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

✍ Eric Tse; Anskar Y. H. Leung; Joycelyn Sim; Harold K. K. Lee; Herman S. Y. Liu; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 98 KB

Clofarabine (40 mg/m^2^/day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m^2^/day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory (__N__ = 4) and relapsed (__N__ = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myel

Sequential high-dose cytosine arabinosid

Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia

✍ Capizzi, Robert L. ;Cheng, Yung-Chi 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

The development of resistance to Ara-C by leukemia cells may be a multifactorial process. These include diminished rates of anabolism or increased rate of catabolism to Ara-C, competition for incorporation into DNA by higher pool size of the competing normal metabolite, dCTP and perhaps other mechan

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%